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Abstract: Apigenin (4′,5,7-trihydroxyflavone) (Api) is an important component of the human
diet, being distributed in a wide number of fruits, vegetables and herbs with the most important
sources being represented by chamomile, celery, celeriac and parsley. This study was designed
for a comprehensive evaluation of Api as an antiproliferative, proapoptotic, antiangiogenic
and immunomodulatory phytocompound. In the set experimental conditions, Api presents
antiproliferative activity against the A375 human melanoma cell line, a G2/M arrest of the cell
cycle and cytotoxic events as revealed by the lactate dehydrogenase release. Caspase 3 activity
was inversely proportional to the Api tested doses, namely 30 µM and 60 µM. Phenomena of early
apoptosis, late apoptosis and necrosis following incubation with Api were detected by Annexin
V-PI double staining. The flavone interfered with the mitochondrial respiration by modulating both
glycolytic and mitochondrial pathways for ATP production. The metabolic activity of human dendritic
cells (DCs) under LPS-activation was clearly attenuated by stimulation with high concentrations
of Api. Il-6 and IL-10 secretion was almost completely blocked while TNF alpha secretion was
reduced by about 60%. Api elicited antiangiogenic properties in a dose-dependent manner. Both
concentrations of Api influenced tumour cell growth and migration, inducing a limited tumour area
inside the application ring, associated with a low number of capillaries.
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1. Introduction
Natural products, either in the form of total extracts or purified active compounds, have been
demonstrated to play a vital role in the current management of different types of cancer, with directions
being pulled toward both treatment and prevention. As proven by current cancer therapy, an increased
number of anticancer drugs used in the clinic are based on natural products obtained from different
sources (plants, animals, microorganisms) [1]. Due to the fact that the biodiversity of our planet has not
been fully exploited, many specialised research institutions, including the National Cancer Institute,
have allocated important funds and brilliant minds in order to use what mother nature provided to
fight the biggest challenge of the 21st century medicine: cancer.
Important studies in the field have shown that the incidence of melanoma has been growing
especially in countries with light skin population [2]. Although melanoma accounts for only around
1% of the types of skin cancers, it is the most dangerous form, as it is responsible for most death cases.
Moreover, the number of Americans diagnosed with skin cancer at a certain point in their lives in the
last thirty years is estimated to be higher than the number of all other cancers summed up [3]. The
standard models of evolution include: (a) benign naevi; (b) dysplastic naevi; (c) melanoma in situ; and
(d) invasive melanoma [4]. The number of papers on PubMed that have the word “melanoma” in their
title exceeds 120,000, thus indicating that melanoma represents a continuing hot topic that is being
approached by an impressive number of different therapeutic strategies.
With respect to the main classes of natural compounds, flavonoids have been intensively studied
as natural compounds with chemo-preventive properties against different types of cancer due to
their biological activities which include antiproliferative and proapoptotic effects [5]. Apigenin
(4′,5,7-trihydroxyflavone) (Api) is a natural compound belonging to the flavone subclass of flavonoids.
The aglycone is part of the chemical composition of some glycosides, the main representatives
being apigetrin, vitexin, isovitexin, apiin [6]. The flavone is an important component of the human
diet, being distributed in a large category of fruits, vegetables and herbs, with the most important
sources being represented by chamomile, celery, celeriac and parsley [7]. Other frequently used
nutraceutics rich in this flavonol include oranges, grapefruit, garlic, and propolis [8]. Venigalla et al.
established that in the case of ligulate flowers of chamomile, apigenin represents around 68% of
the total flavonoids [9]. Apigenin has been described by numerous in vitro and in vivo studies in
the field, using various cancer cell lines as a natural compound with chemo-preventive activity and
tumour growth inhibition potential [10–12]. The relationship between cancer and inflammation is
very well defined in the scholarly literature [13]. Following a complex study, Perrott et al. assigned
apigenin some anti-inflammatory properties [14]. A current comprehensive review describes other
biological properties of apigenin as follows: prevention of cardiovascular diseases due to different
causes (atherosclerosis, hypertension, cardiac hypertrophy, induced heart injury), protective effect on
the liver, on the respiratory system, on the endocrine system, on central nervous system, on bones and
joins [8].
A recent paper has reported that the flavone exhibited antiproliferative, anti-invasive and
proapoptotic properties in vitro against two human cancer cell lines, namely A375 and C8161 [15].
Following the same train of thought, a study conducted by Caltagirone et al. confirmed apigenin and
quercetin as active compounds presenting the potential to inhibit melanoma onset and metastatic
spreading in a murine model of melanoma designed by the injection of B16-BL6 cells into C57BL/6N
mice [16]. This approach was investigated in more detail by the group of Piantelli et al., who assigned the
anti-metastatic effect to a mechanism that involves impairing tumour cell endothelium interactions [17].
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Using B16-F10 cell injection into syngeneic mice, Cao et al. proposed an additional mechanism, namely
the inhibition of the STAT3 signalling pathway [18].
The aim of this study was to assess the antiproliferative, proapoptotic, antiangiogenic properties,
the modulation of mitochondrial respiratory chain and the glycolysis by this flavone against A375
human melanoma cells, as well as to analyse its immunomodulatory effect in human dendritic cells.
2. Materials and Methods
Apigenin ≥99% (HPLC) (CAS Number 520-36-5) (Api) was acquired from Sigma-Aldrich,
Steinheim, Germany.
2.1. Cell Culture and Preparation
The human melanoma (A375) cell line (ECACC; Sigma Aldrich origin Japan stored UK) was
grown into Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco BRL, Invitrogen, Carlsbad, CA,
USA) supplemented with 1% penicillin/streptomycin mixture (Pen/Strep, 10,000 IU/mL; PromoCell,
Heidelberg, Germany) and 10% foetal calf serum (FCS; PromoCell, Heidelberg, Germany). At 80–90%
confluence, the cells were passaged following treatment with EDTA (5 mM).
Human dendritic cells were differentiated from isolated PBMCs by buffy coats, as described
previously [19]. Briefly, Ficoll (GE Healthcare, Uppsala, Sweden) was used for density centrifugation.
Several (2 × 108) cells per well of isolated, PBMCs were plated, and the supernatant was discarded
upon 2 h of plastic adherence. Afterwards, RPMI 1640 GlutaMax medium (Thermo Fisher Scientific,
Boston, MA, USA) was used for cell differentiation. The medium was supplemented with 100 IU/mL
penicillin, 100 µg/mL streptomycin with 10% FCS, 10 mM HEPES (Sigma-Aldrich, Steinheim, Germany),
1 mM sodium pyruvate and 50 µM 2-β-ME (Thermo Fisher Scientific, Boston, MA, USA) supplemented
with 40 ng/mL recombinant human GM-CSF (Peprotech, NJ, USA) and human IL4 (Peprotech, NJ,
USA); the medium was renewed after 4 days.
Differentiated cells were collected by cell scraping and transferred to 6-well plates for further
experiments or to tissue treated 8-well chambered cover slides (Ibidi, Martinsried, Germany) for
fluorescence microscopy staining. The supernatants were tested for TNF-alpha IL-10 and IL-6 (R&D
Systems, Wiesbaden, Germany) by ELISAs according to the manufacturer’s protocol.
2.2. Cell Viability Assays
The antiproliferative property of Api was determined by means of MTT (Sigma-Aldrich, Budapest,
Hungary) assay against A375 human melanoma cells. Experiments were carried out as described
previously [20]. Briefly, cells were seeded into 96-well plates (5000 cells/well) and treated with different
concentrations of Api (0.3–60.0µM) under standard conditions (37 ◦C, 5% CO2). After 72 h of incubation,
5 mg/mL MTT solution was added and the microplates were incubated for an additional 4 h. The
resulting formazan crystals were dissolved in dimethyl sulfoxide and the absorbance was determined
at 545 nm with an ELISA reader (Awareness Technology, Palm City, FL, USA). Cisplatin, a clinically
used anticancer agent was applied as a reference agent. Sigmoidal concentration–response curves
were fitted to the determined results and IC50 values were calculated by means of GraphPad Prism
(GraphPad Software, San Diego, CA, USA).
For cells viability assessment, the XTT assay (Thermo Fischer Scientific) was used according to the
manufacturer on human dendritic cells. Briefly, the final XTT solution was put on wells with cells or
medium only as a control. After 45 min incubation time at 37 ◦C and 5% CO2, aliquots of the cells were
assessed in flat 96-well plates (Greiner, Frickenhausen, Germany) at 460 and normalised to 650 nm.
Previously, cells had been stimulated with the vehicle or with Api, in the presence or absence of LPS
for 24 h and 48 h at the indicated concentrations. After XTT assay, the cell number was obtained and
normalised to 104 cells.
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2.3. Cell Cycle Analysis by Flow Cytometry
To describe cell cycle distribution, the DNA content of the cells was determined by flow cytometry.
A375 cells were plated into 6-well plates (300,000–400,000 cells/well) and pre-incubated for 24 h. Then
the cells were washed twice with cold phosphate-buffered saline (PBS), trypsinised and centrifuged
(1500 rpm, 10 min). Cells were washed and fixed in 1 mL of cold ice 70% ethanol for 30 min. Samples
were treated with dye solution containing RNAse A (0.02 mg/mL), propidium iodide (0.1 mg/mL),
Triton-X (0.003 mL/mL) and sodium citrate (1.0 mg/mL) in distilled water and the mixtures were kept in
the dark for one hour at room temperature. DNA content of the cells was analysed by a Partec CyFlow
flow cytometer (Partec GmbH, Münster, Germany). In each sample, 20,000 cells were assessed, and the
proportion of the cells in the different cell cycle phases (subG1, G1, S and G2/M) were calculated using
ModFit (Verity Software House, Topsham, ME, USA).
2.4. Anti-Migratory Potential—Scratch Assay Method
For the assessment of the regressive effect of Api on the invasion capacity of the human
melanoma-A375 cell line, the scratch assay test was performed. Several 2 × 105 cells/well were
seeded onto 12-well culture plates until 90% confluence was reached. After that, the attached cells were
scratched following the diameter of the well using a sterile pipette tip. The detached cells and cellular
debris were removed by gently washing the wells with PBS. Furthermore, the cells were stimulated
with Api at two different concentrations 30 µM and 60 µM. Wells were captured on images at 0 h and
24 h, in order to compare the cell growth of the stimulated vs. control (no stimulation) cells in early
stages and at consistent times. Each well was marked below with a line, to improve identification of
the same imaging area. Images were taken with Olympus IX73 inverted microscope provided with
DP74 camera (Olympus, Tokyo, Japan) and cellSense Dimension software was used for analysing the
cell growth. To quantify the migratory ability of the cells, the wound closure percentage was calculated
as previously described [21].
2.5. Determination of In Situ Caspase Activity
Caspase-3 is one of the key players in the apoptotic machinery. To determine the effects of Api on
the activity of caspase-3, a colorimetric assay (Sigma-Aldrich, Budapest, Hungary) was performed.
Ten and 12 million cells were plated in tissue culture flasks for control and treatment condition,
respectively. After 24 h of pre-incubation, the cells were treated with Api (30 uM or 60 uM) for
48 h. Then cells were sampled, counted, centrifuged, washed with PBS and re-suspended in kit lysis
buffer (107 cells/100 µL), and incubated on ice for 20 min. The lysate was centrifuged, and the protein
concentration of the supernatant was determined (Pierce Biotechnology, Rockford, IL, USA). According
to the manufacturer’s protocol, 5.0 µL portions of treated and control lysates were incubated with
10 µL selective substrate of the enzyme (acetyl-Asp-Glu-Val-Asp-p-nitroaniline) in a final volume of
100 µL buffer. After a night of incubation at cell culture conditions, the absorbance of p-nitroaniline
was measured at 405 nm with an ELISA reader. The treatment-related change in the caspase activity
was expressed as fold increase.
2.6. Annexin V—Propidium Iodide Assay
Into 6-well plates (Greiner bio-one), 5 × 105 cells/well were seeded and allowed to attach to the
bottom of the plate overnight. After 24 h, the cultured medium (DMEM) was thrown and a fresh one
containing Api at the highest concentration (60 µM) was added. Starting from a stock solution of 10
mM Api in DMSO, successive dilutions into the medium were performed in order to obtain the final
concentration of the tested compounds. As a control sample, untreated cells were used; cells incubated
with DMSO were used as solvent control. After 72 h, the cells were trypsinised and analysed for the
apoptotic effect of the tested compounds using flow cytometry. Annexin V-FITC mixed with propidium
iodide (PI) kit (Invitrogen, ThermoFisher, Vienna, Austria) was used for cell death flow cytometric
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studies (apoptosis) according to the manufacturer’s manual. In brief, 2–5 × 105 cells were washed two
times in 1 × Annexin V binding buffer, and then centrifuged at 1,500 RPM for 5 min, re-suspended in
the binding buffer and incubated with 5 µL of Annexin V-FITC in the dark for 15 min. After the cells
were washed with 200 µL of the specific binding buffer and then centrifuged, the cell pellet obtained
was re-suspended in a volume of 190 µL binding buffer, and immediately prior to analysis by flow
cytometry 10 µL of PI solution was added.
2.7. Assessment of Cytotoxicity via LDH Released
Lactate dehydrogenase (LDH) assay kit (No 88954, Thermo Fisher Scientific, Boston, MA, USA)
was employed to determine the cytotoxic effect of Api and DMSO at concentration of 30µM and 60 µM
on the human melanoma A375 cell line. This technique is based on the cytosolic enzyme released
(LDH) into the media which can be further quantified by an enzymatic reaction, leading to formazan
production. The level of formazan is directly proportional to LDH leakage into the media, which is an
indicative of the cytotoxic effect.
Briefly, 5000 cells/well in 200 µM specific media were cultured in 96-well plate and allowed to
attach overnight. The next day, the cells were treated with Api and DMSO at concentration of 30 µM
and 60 µM and incubated for 72 h. After this step, the LDH released into the media was transferred
into a new 96-well plate, followed by an addition of reaction mixture. The plate was incubated at
room temperature, protected from light; stop solution was added after 30 min. The concentration of
formazan is measured at 490 nm and 680 nm wavelengths via spectrophotometry with a microplate
reader (xMarkTMMicroplate, Serial No. 10578, Biorad, Japan).
2.8. Fluorescence Microscopy
Tissue-treated 8-well chambered cover slides (Ibidi, Martinsried, Germany) were used for
dendritic cells growth. The cells were cultured and fixed as previously described [19]. DAPI
(4′,6-Diamidine-2′-phenylindole dihydrochloride) solution (Roche Diagnostics, Mannheim, Germany)
and phalloidin Alexa Flour 488 solution (Thermo Fisher) were applied for 1 h. A Zeiss LSM510
Meta system equipped with an inverted Observer Z1 microscope and a Plan-Apochromat 63× /1.4 oil
immersion objective (Carl Zeiss MicroImaging GmbH, Göttingen, Germany) were used for confocal
laser scanning microscopy.
2.9. Extracellular Flux (XF) Analysis
A375 cells (2 × 104 cells/well) were seeded in Seahorse 24-well cell culture plates and allowed to
attach overnight. On the second day, the cells were stimulated with two concentrations of Api (30 and
60 µM) or with DMSO; the control group is represented by untreated cells, incubated only with cell
culture medium. Background correction wells (wells that were not seeded with cells) were included in
the assay, in order to normalise the data to background plate noise. Cells were incubated at 37 ◦C and
5% CO2 with the samples for 72 h.
The cells were divided into five groups: control—untreated cells; cells treated with DMSO; and
cells treated with Api 30 µM and Api 60 µM, respectively. The oxygen consumption rate (OCR) and
extracellular acidification rate (ECAR) were measured using the Seahorse XFe24 (Seahorse Agilent)
extracellular flux analyser, as previously described [22]. Three injections were performed in order to
change cells metabolism, namely: oligomycin (1 µg/mL)—a complex V inhibitor; FCCP (3 µM)—a
classic uncoupling agent, and antimycin A+Rotenone (2.5 µM + 2 µM)—inhibitors of complex I and
III, respectively [23]. The OCR parameters recorded in the analysis were as follows: (i) the basal
respiration (before oligomycin addition); (ii) the leak state (after oligomycin addition)—the amount
of O2 consumption needed to sustain the proton gradient; (iii) the maximal respiration (after FCCP
addition)—respiration in the presence of a classic uncoupler of oxidative phosphorylation; (iv) the
ATP turnover (the difference between the basal respiration and the leak state)—the amount of O2
consumption used for ATP production; (v) the reserve capacity (the difference between the maximal
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and the basal respiration). The reserve capacity is a fundamental parameter of cellular bioenergetics,
and shows the capacity to respond to an increased energy demand [24]. OCR was reported in units of
pmoles/minute and ECAR in mpH/minute.
2.10. Chorioallantoic Membrane Assay (CAM)
The CAM assay involves the use of fertilised hen (Gallus gallus domesticus) eggs. We implemented
a slightly modified technique developed by Ribatti et al. [25]. Briefly, the general method includes
egg disinfection with 70% ethanol prior to incubation at controlled 37 ◦C and 50% humidity. On the
third day of incubation, noted as the embryonic day of development (EDD 3), 3–4 mL of albumen was
removed, followed by cutting and resealing a window on the upper side of the eggs on EDD 4. In
ovo macroscopic assessment was performed in daytime by means of a stereomicroscope (Discovery 8
Stereomicroscope, Zeiss). For further morphometric analysis, significant images were registered on a
daily basis, using the Axio CAM 105 colour, Zeiss digital camera and processed by Zeiss ZEN software,
ImageJ and GIMP.
The morphometric evaluation of the angiogenic reaction can be assessed using different approaches,
namely semi-quantitative scales [26] or equations [27–29]. In this study, macroscopic images were used
in order to count the number of blood vessels (BV) intersecting the inoculation ring. Angiogenesis
inhibition (AI) can be expressed in percentages using the following equation:
AI (%) = (1 − No BVtest/No BVcontrol) × 100. (1)
2.11. Normal Angiogenesis Assessment on the Chorioallantoic Membrane
Firstly, we assessed the effects induced by Api on the normal developing CAM. This type of assay
is indicative for the tolerability of Api on normal tissues, but also stands for the predictability of its
implications on highly angiogenic blood vessels (between EDD 7–10). Starting on EDD 7 (day 0, 0 h)
three test groups of samples were designed: (a) Api in 30 µM (API 30) concentration; (b) Api in 60 µM
(API 60) concentration; (c) DMSO 1% as solvent control (1% DMSO v/v in double distilled water). All
samples in volumes of 5 µL/egg were applied directly inside a plastic ring placed on top of the CAM.
The assessment was carried out for 48 h, representing a medium-term tolerability assessment.
2.12. Tumour Angiogenesis Assessment on the Chorioallantoic Membrane
The assessment of Api in an in vivo melanoma model using the CAM assay requires the inoculation
of the melanoma cells on top of the developing membrane on EDD 10 (day 0, 0 h). A375 melanoma
cells were cultured according to the above described protocol and subsequently inoculated onto the
CAMs [30]. Briefly, after detaching the cells from the culture plate by trypsinisation, they were cleansed
and re-suspended in the culture medium until reaching the final concentration of 105/5 µL. On the
10th day of incubation, 5 µL of the melanoma cell suspension was inoculated inside a plastic ring
previously placed on the CAM. All specimens were inoculated with 5 µl of A375 melanoma cells and
were divided in three test groups: (a) Api in 30 µM concentration; (b) Api in 60 µM concentration;
(c) DMSO 1% as solvent control. Each test solution was applied in volumes of 5 µl and was repeated
daily for 96 h, until EDD 14. Relevant images were captured every day in vivo, and on the final day
of the experiment, after detaching the fine membranes of the tested specimens, ex vivo images were
also taken. The same type of angiogenesis analysis as described for the normal tested CAMs was
performed for the melanoma treated specimens.
2.13. Statistics
The Prism software package (Graph Pad Prism 5.0 for Windows) was used for data collection
and presentation. The data ranged from three to five separate experiments is presented as the mean ±
SD. An unpaired Student’s t-test, one-way ANOVA or two-way ANOVA followed by a Bonferroni
post-test or Newman-Keuls post-test were used to determine the significant differences between the
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various experimental and control groups. A paired Student’s t-test was used to determine significant
differences in all experiments concerning dendritic cells. *, **, ***, **** indicate p < 0.05, p < 0.01,
p < 0.001 and p < 0.0001, respectively, compared to the control group or otherwise-indicated groups.
3. Results
3.1. Cell Growth Inhibition
As can be observed in Figure 1, in the range of tested concentrations, Api presents substantial
antiproliferative effect against A375 human melanoma cell line starting from the 30 µM concentration.
The calculated IC50 is 33.02 µM.
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Figure 1. Cell growth inhibition (%) ± SEM against A375 human melanoma cells after 72 h of incubation
with Api. * p < 0.05; *** p < 0.001.
3.2. Api Effects on Cell Cycle Phases
To have a complete picture of the antiproliferative effect, the concentrations that led to this kind of
event, namely 30 µM and 60 µM Api, were used to analyse the effect on the phases of the cell cycle.
Results showed that in the case of both concentrations, Api induced a G2/M arrest by increasing the
percentage of A375 cells in this phase of the cell cycle from 18.946 ± 1.91% (control) to 33.423 ± 0.15%
(30 µM Api) and 33.653 ± 0.96% (60 µM Api). Results are described in Figure 2.
3.3. Antiproliferative Effect of Api
As shown in Figure 3, both concentrations of Api (30 µM and 60 µM) manifested a significant
inhibitory effect on the migratory capacity of human melanoma A375 cells, when compared to the
migratory ability of control cells. Human melanoma A375 cells displayed wound width modifications
of only 38 µm, from 575.05 µm to 537.59 µm, after treatment with Api 60 µM and from 550.84 µm to
418.90 µm after stimulation with Api 30 µM in a 24 h timeframe. The wound healing rate induced after
Api treatment at 30 µM and 60 µM concentrations was 23% and 6.84%, respectively. This means that
the inhibitory rate expressed by Api (30, 60 µM) on cell migration was 77% and 93.16%, respectively.
However, the control cells (no stimulation) displayed a good wound healing rate above 77% after 24 h.
In addition, it can be observed that cells showed apoptotic characteristics by changing their
shape and morphology, followed by cell detachment after 24 h, after stimulation with Api at
60 µM concentration.
The aforementioned data show that in the set experimental conditions Api exhibits
antiproliferative potential.
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3.4. Caspase 3 Activity
A new set of experiments was conducted in order to gain insights about potential proapoptotic
and/or cytotoxic effect. In this type of experiment, the Hormesis phenomena can be observed to
be characterised by a biphasic response. An increased activity of protein caspase 3 following 72 h
of incubation with Api 30 µM was observed. Interestingly, Api 60 µM did not enhance caspase 3
Nutrients 2019, 11, 858 9 of 19
activity, presumably because of a cytotoxic effect at this concentration/incubation time (Figure 4).
Also, the expression of caspase 2 and p53 proteins was analysed by immunocytochemistry, but none
of these proteins were expressed following incubation with the highest tested concentration of Api
(Supplementary Figure S1).
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Api at the tested concentrations (30 µM, 60 µM) induced both early and late apoptosis phenomena,
as well as necrosis. As can be seen from Figure 5, where the means of three different experiments
are represented, Api 30 µM caused preponderantly early apoptotic events (8.5 ± 1.8% vs. 86.25% ±
1.8 with respect to Control), while Api 60 µM (12.25 ± 2.9% vs. 77.5 ± 3.2% with respect to Control)
induced predominantly late apoptotic events.
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3.6. LDH Assay
To gain more information regarding the cytotoxic potential of Api at the selected concentrations,
lactate dehydrogenase assay was perfo med. After 72 h, a significant difference was observ d in
the release of lactate dehydrogenase between A i 30 µM (cytotoxicity rate of 20.75%) and DMSO
(cytotoxic ty rate of 1.12%). However, increment of Api concentration at 60 µM did not increase its
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cytotoxic effect on the human melanoma A375 cell line, showing a cytotoxic effect of almost 19%.
Results are presented in Figure 6.
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3.7. Bioenergetic Profile of A375 Human Melanoma Cells
Within this study we also assess d the Api effect on cellular bioenergetics in A375 human
melanoma cells. The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were
measured at 72 h post-treatment of A375 human melanoma cells with two concentrations of Api (30 and
60 µM) using the Seahorse XFe24 (Seahorse Agilent) extracellular flux analyser. Results describing the
bioenergetic profile of A375 human melanoma cells at 72 h post-stimulation are presented in Figure 7.Nutrients 2019, 11, x FOR PEER REVIEW 11 of 19 
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e observed that in the basal respiration state, the cells are in the unchallenged state. Treatment
with Api induced a significant dose-dependent decrease in the baseline rates (basal respiration for
Api 30 µM→ 137.9 ± 31.4 pmols/min vs. Control→ 266.07 ± 20.8 pmols/min; Api 60 µM→ 22.2 ±
5.5 pmols/min vs. Control). In the leakage state, there is a decrease in the OCR due to blockage of ATP
production following oligomycin injection. At the higher employed dose—60 µM Api—a decrease in
the proton leak state (34.9 ± 7.1 pmols/min vs. Control→ 135.01 ± 14.6 pmols/min) and in the maximal
respiratio rate (12.4 ± 5.3 pmols/min vs. Control→ 46.5 ± 5.9 pmols/min) was elicited.
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After adding the respiratory chain uncoupling agent (FCCP), there is normally an increase in
the O2 consumption due to the uncoupling mechanism. In our case, the maximal respiration was
lower than the basal respiration, because in the case of tumour cells, there is a shift to a glycolytic state.
The maximal respiration for Api 30 µM is 53.3 ± 6.9 pmols/min, whereas for Api 60 µM a value of
12.4 ± 5.3 pmols/min was recorded. Furthermore, the ATP turnover also displayed a decrease after
stimulation with Api. This effect was recorded for Api in both tested doses and also in the case of
DMSO, at the higher tested dose, 60 µM (ATP turnover for Api 30 µM was -12.65 ± 6.5 pmols/min vs.
Control 131.05 ± 7.1 pmols/min and for Api 60 µM it was 22.1 ± 8.3 pmols/min vs. Control).
As previously mentioned, the reserve capacity represents the difference between the maximal and
the basal respiration, and due to the fact that the first recorded lower values than the basal respiration,
we obtained negative values. Our data indicate that treatment with Api decreased A375 tumour cells
reserve capacity considerably, which proves that it is more difficult for treated cancer cells to respond
to stress than untreated cells or cells treated with DMSO (Reserve capacity for Api 30 µM→−9.8 ±
5.8 pmols/min vs. Control→−219.5 ± 24.5 pmols/min and for Api 60 µM→−84.6 ± 31.4 pmols/min
vs. Control).
In the DMSO groups, there is a slight increase in ECAR, whereas in the Api groups, there
is a significant dose-dependent decrease of ECAR, indicating that the compound also induced an
impairment in cellular glycolytic activity (Api 30 µM→ 11.4 ± 2.8 mpH/min vs. Control→ 65.04 ±
1.5 mpH/min and for Api 60 µM→ 45.1 ± 7 mpH/min vs. Control). Our results indicate a significant
alteration of the bioenergetic profile in A375 human melanoma cells treated with 60 µM Api, an effect
that might emphasise its beneficial properties against tumour cells.
3.8. Immunomodulatory Effects of Api
To test the immunomodulatory effects of Api, primary peripheral blood mononuclear cells
(PBMCs) were isolated from human blood, differentiated into dendritic cells (DCs), and stimulated with
corresponding amounts of Api. Cell expansion of human dendritic cells after 24 h with vehicle, Api in
different concentrations, or DMSO in the absence (naïve) or presence of LPS, as well as representative
transmitted light microscopic images of Api-stimulated human dendritic cells after 24 h in the absence
(native) or presence of LPS, are presented in Figure 8a,b.
As expected, vehicle- and DMSO-treated cells expanded within 24 h of lipopolysaccharide (LPS)
activation (Figure 8a). This cell expansion was completely abrogated by parallel stimulation of 30
and 60 µM Api, while low-dose Api (1µM) had no effect compared to control. Transmitted light
microscopic images highlight the strong effect of Api on cell morphology (Figure 8b). The cells acquired
a round shape upon high-dose Api stimulation. Moreover, LPS stimulation failed to provoke the
typical development of dendrites as seen in the control cells or at the low dose of Api.
3.9. XTT Assay for Metabolic Activity
The metabolic activity of human DCs under LPS-activation was clearly impaired by stimulation
with high concentrations of Api with 24 h and even stronger within 48 h (Figure 9a). Confocal
microscopy performed 48 h after stimulation revealed substantial cell damage with 60 µM Api
stimulation, while control cells appeared normal (Figure 9b, upper panel). Furthermore, LPS activation
led to a typical aggregation of DCs to cell-clusters under control conditions, which was not present
under a high dose of Api stimulation (lower panel).
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TNF-alpha secretion, possibly because of some induced increase in the membrane permeability, the 
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Figure 9. (a) XTT assay for metabolic activity of human dendritic cells stimulated with vehicle, Api in
different concentrations or DMSO in the presence of LPS for 24 h and 48 h. (b) Representative confocal
microscopic images of human dendritic cells treated with vehicle or 60 µM Api in absence (upper panel)
or presence (lower panel) of LPS for 48 h (magnification 63x). Data are expressed as mean ± standard
deviation (SD); significant differences are indicated as ** p < 0.01; ## p < 0.01, # p < 0.05; n = 4.
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3.10. Cytokine Quantification
Cytokine secretion was analysed in order to see if the reduced cell activity of LPS-stimulated
cells had functional consequences. Even though DMSO led to a significant increase in IL-6 and
TNF-alpha secretion, possibly because of some induced increase in the membrane permeability, the
cytokine secretion was very strongly blocked by higher concentrations of Api (Figure 10). IL-6 and
IL-10 secretion was almost completely blocked by 30 and 60 µM stimulation with Api and TNF alpha
secretion was reduced by about 60%. The low dose of Api had no effect compared to the control
secretion in all cytokines.
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3.11. Chorioallantoic Membrane Assay
Using the in vivo chick chorioallantoic membrane assay, we investigated in ovo the tolerability
and potential influence of Api on the normal and tumoural angiogenic process, next to the effect
produced directly on the development of A375 melanoma cells. The assessment of Api in 30 and 60 µM
concentrations was performed compared to the solvent control, diluted DMSO.
Firstly, we used the normal angiogenesis type of assay in order to assess the biocompatibility
and tolerability. Survival rates of the embryos were similar for both concentrations of Api and the
solvent control. However, some differences were observed concerning the inflammatory and irritation
responses or the development of the CAM. Api in 60 µM concentration induced an irritation and fibrotic
process that involved a higher number of capillaries surrounding the lesioned area. By testing the
compound during a time-frame characterised by a rapid mitotic index and growth of endothelial cells,
we were also able to assess the influence of Api on such a process. Interestingly, the low concentration
showed a more important effect of reducing the number of capillaries inside the application area. Api
at 60 µM induced a reduced inhibition of the angiogenesis, compared to Api at 30 µM, but still higher
than the control (Figure 11).
When tested on the tumour model in the CAM assay, using A375 melanoma cells (Figure 12),
the influence of Api on tumour cells was also assessed, next to the influence of the compound on the
tumour angiogenic process. Both concentrations of Api influenced tumour cell growth and migration,
inducing a limited tumour area inside the application ring, associated with a low number of capillaries.
Still, the migration of melanoma cells was not totally inhibited, areas of cells were observed outside the
ring and spokes wheel pattern of vessels converging on the tumour cells.
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the influence of Api on tumour cells was also assessed, next to the influence of the compound on the 
tumour angiogenic process. Both concentrations of Api influenced tumour cell growth and 
migration, inducing a limited tumour area inside the application ring, associated with a low number 
of capillaries. Still, the migration of melanoma cells was not totally inhibited, areas of cells were 
observed outside the ring and spokes wheel pattern of vessels converging on the tumour cells. 
Differences noticed consist of the effect induced by the two concentrations of Api. A reduced 
number of cells with minimal aggregation pattern were observed for the low concentration of Api 
(30 μM). The number of vessels inside the ring was also reduced, with capillaries showing 
irregularities. The higher concentration (30 μM) also showed a limited growth of tumour cells inside 
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inhibited compared to the low concentration, possibly owing to the irritation potential that was 
observed in the normal setting of CAM assay. Still, the differences between the two concentrations 
are reduced in the tumour angiogenesis model, and both are significantly more active in 
angiogenesis inhibitors compared to the control. 
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Differences noticed consist of the effect induced by the two concentrations of Api. A reduced
number of cells with minimal aggregation pattern were observed for the low concentration of Api
(30 µM). The number of vessels inside the ring was also reduced, with capillaries showing irregularities.
The higher concentration (30 µM) also showed a limited growth of tumour cells inside the ring, with
reduced number of interconnected capillaries, though; the vascularisation was less inhibited compared
to the low concentration, possibly owing to the irritation potential that was observed in the normal
setting of CAM assay. Still, the differences between the two concentrations are reduced in the tumour
angiogenesis model, and both are significantly more active in angiogenesis inhibitors compared to
the control.
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4. Discussion
In this study, we have demonstrated that Api is an antiproliferative and proapoptotic agent
against the A375 human melanoma cell line, leading to an IC50 of 33.02 µM for the tested dose ranges
(0.3–60 µM). The same conclusion was drawn by the group of Zhao et al. [15]. In their approach,
in order to assess the antiproliferative potential, two melanoma cell lines were used, namely A375
and C8161, and concentrations in the interval of 40–240 µM with check points at 24 h, 48 h, 72 h
and 96 h. Api inhibited proliferation in a dose-dependent manner, as well as in a time-dependent
manner. Moreover, Api inhibited migration at the 40 and 80 µM concentrations after 24 h of exposure,
but the effect was abolished at 100 µM. Relative to the invasion, Api inhibited this process at 40 µM
concentrations after 72 h of exposure, but again the effect was abolished at 80 µM. Using a higher
concentration than in our study, namely 100 µM, they also demonstrated that Api causes a G2/M arrest
in the two selected melanoma cell lines. They also detected apoptotic events after 24 h of exposure
at 40 and 80 µM [15]. The ability of this flavone to arrest the cell cycle in the G2/M phase in the case
of epidermoid carcinoma A431 cells was postulated by Chan et al. [31]. Hasnat et al., using A375
and A2058 human melanoma cell lines, showed that Api in 50 µM concentration and after a period
of incubation of 24 h significantly decreased the number and viability and altered the morphology
of selected cells [32]. As discussed in the results section of our study, we have demonstrated that
Api at 30 µM concentration and after a period of 72 h induced caspase 3 activation; however, when
60 µM was applied, the concentration of caspase 3 decreased as compared to control, presumably
because of a cytotoxic effect at this concentration and timeframe. The assessment of the cytotoxicity
was also performed by quantifying the amount of LDH, a cytosolic enzyme which is released by the
cells undergoing necrosis [33,34]. However, the sensitivity of this technique is questionable when cells
are exposed to compounds that induce cell cycle arrest [35]. Due to the fact that cells no longer express
proliferative properties, the amount of LDH that can be released from the cells will be quite low, thus
undermining the sample-induced cytotoxic effect. This phenomenon was also observed in our case for
the A375 human melanoma cells stimulated with Api 60 µM. A more intense cytotoxic effect manifested
by Api at 60 µM compared to the effect induced by Api at 30 µM cannot be disputed, as shown by the
images performed during LDH assessment (Figure S2); yet, under these conditions, the LDH technique
yielded diminished cytotoxicity results. Using the Western blot analysis, Zhao et al. showed that
after 24 h of incubation, Api 100 µM augmented the expression of cleaved caspase-3 in the case of
A375 and C8161 human melanoma cells [15]. In an in vivo study, Caltagirone et al. demonstrated
that this flavonoid administrated intraperitoneally in mice bearing a murine model of melanoma by
employing B16-BL6 cells led to a dose-dependent delay of tumour growth and decreased the number
of B16-BL6 colonies in the lungs. Moreover, they showed that the phytocompound is not toxic and is
able to potentiate the activity of cisplatin [16]. Along the same line of thought, Cao et al. published that
the dietary flavonoid suppressed metastasis in mice bearing B16F10 lung tumours and also inhibited
invasion and migration in both human and murine melanoma cell lines. A possible mechanism was
assigned to the inhibition of the STAT3 signalling pathway [18]. Chao et al. showed that in the case
of different human uveal melanoma cell lines, Api inhibits expression and secretion of VEGF by a
mechanism that involves suppression of ERK1/2 and PI3K/Akt pathways [36]. Das et al. used Api
obtained from an ethanoic extract of the plant Lycopodium clavatum (LC) and assessed the anticancer
potential using both the A375 human melanoma cell line and the A549 human lung cancer cell line in
the 20–250 µg/mL dose range interval. Their study also confirmed the in vitro antiproliferative potential
against the melanoma cell line and proposed it as a mechanism for apoptosis DNA interaction, damage
and mitochondrial dysfunction by the direct activity on mitochondrial oxidative phosphorylation
system [37].
In the last decade, several studies have reported that Api can directly target mitochondria in tumour
cell lines, revealing the activation of the mitochondrial apoptotic pathway; Api is associated with
DNA fragmentation, production of reactive oxygen species, mitochondrial membrane depolarisation,
release of cytochrome c and up-regulation of Bax, caspase 3, 9 and PARF [38–40]. Furthermore, it
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has been shown that Api mediates mitochondrial dysfunction in melanoma cells, namely disrupting
the oxidative phosphorylation system of the A375 melanoma cell line [37]. However, the authors
did not indicate whether there is impairment in the glycolytic state after Api treatment. Usually, the
ECAR increase as a consequence of the cells effort to generate ATP in order to maintain their energy
balance [41]. As previously mentioned, our data showed a significant alteration in the A375 human
melanoma cells bioenergetic profile after the treatment with Api, especially at the higher tested dose,
60 µM, an effect that might be correlated with its beneficial effects against melanoma. To the best of our
knowledge, this is the first approach that presents the effects of Api on both mitochondrial respiration
and glycolysis on A375 human melanoma cells.
It is very well known that the immune system plays a crucial role with respect to development
as well as resolution of malignant lesions [42]. The main ‘effectors’ for the activation of the adaptive
immune system are the dendritic cells (DCs). These sentinels of the immune system have the ability
to cross-present exogenous antigens to T lymphocytes [43]. On human dendritic cells, pure Api
completely blocked normal LPS-mediated cell activation. Moreover, the high dose of Api even reduced
typical metabolic activity of DCs. This effect was strongly reflected in a complete abrogation of the
cytokine secretion of IL-6 and IL-10. We have previously shown that natural sources of Api, e.g.,
chamomile extracts containing about 34.103µg/100 µg extract of apigenin glucoside, or 1.388 µg/100 µg
extract of apigenin, also had an effect on dendritic cell activation, although this effect was very minor
compared to the pure, high dose of Api [20]. Also, the secretion of the mentioned cytokines was
not reduced by chamomile extracts. Obviously, a strong concentration-dependent correlation of Api
and its DC immunomodulatory effect is highlighted in the former and the current study. High doses
of Api are potentially able to reduce inflammatory responses to a high extend. While Api reduces
the survival of cancer cells, as indicated in this study on human melanoma cells, the effect of Api as
a potential immune response suppressor has to be taken into account when considering Api as an
anti-cancer agent.
Recently, Api has been studied intensively, and anticancer effects have been documented, with a
possible efficacy for limiting cancer progression. Angiogenesis mediated anticancer activity is being
reported in several studies, on various cancer types (e.g., lung cancer, prostate cancer, skin cancer,
neuroblastoma, breast cancer) by modulating different pathways [44]. The effect was described for
lung and colon cancer cells on the chorioallantoic membrane and was correlated with the decrease
in the HIF-1 and VEGF expression at 20 µM concentration [45]. Our study indicated a better effect
on angiogenesis inhibition in normal conditions and in the presence of melanoma cells, at 30 µM
concentration, but not at 60 µM, a concentration which induced irritation phenomena on the CAM.
Shankar et al. showed the effect on melanoma lung metastasis by impairing the interactions between
tumour cells and the endothelial cells [44]. Little data is available on the effects of Api in vivo using
the chorioallantoic membrane assay in the case of human melanoma.
5. Conclusions
The comprehensive assessment of Api against the A375 human melanoma cancer cell line
shows that under the set experimental conditions, the flavone presents an anticancer mechanism that
involves inhibition of proliferation, induction of apoptosis, modulation of bioenergetics profile and
inhibition of angiogenesis. However, under the aforementioned parameters, Api does not show any
immune-stimulatory properties.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/4/858/s1,
Figure S1: Expression of caspase 2 and p53 proteins after stimulation with Api 60 µM vs. Control, Figure S2:
Morphological aspects of human melanoma A375 cells exposed to Api at concentrations of 30 µM and 60 µM
during LDH assessment. Images were taken 72 h post-treatment.
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